

Reference:	FOI.20538.26
Subject:	Biologics in Secondary Care
Date of Request:	28 May 2026

Request and response:

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of January 2026 and the end of March 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organisation.

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients for some of the medications due to the low number (less than 5) and have therefore, replaced the figures in the tables with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

The UHB provides within the table below, the number of patients treated with the listed medications, for any condition, during the period 1 February to 30 April 2026, the most recent period the data is available.

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	86
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	159
1.4 Lebrikizumab (Ebglyss)	5
1.5 Mepolizumab (Nucala)	26
1.6 Omalizumab (Xolair)	12
1.7 Reslizumab (Cinqaero)	0
1.8 Tezepelumab (Tezspire)	160

2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

The UHB provides within the table overleaf, the number of patients treated for the conditions with the medications listed, during the period 1 February to 30 April 2026.

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
2.1 Benralizumab (Fasenra)	84	0	0
2.2 Depemokimab (Exdensur)	0	0	0
2.3 Dupilumab (Dupixent)	18	0	0
2.4 Mepolizumab (Nucala)	26	0	0
2.5 Omalizumab (Xolair)	*	0	0
2.6 Reslizumab (Cinqaero)	0	0	0
2.7 Tezepelumab (Tezspire)	160	0	0

3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

The UHB provides within the table below the number of patients treated for Atopic Dermatitis (AD) with the listed medications, during the period 1 February to 30 April 2026.

Name of medicine	Number of patients with AD
3.1 Dupilumab (Dupixent)	139
3.2 Lebrikizumab (Ebglyss)	5

4. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

The UHB provides within the table below, the number of patients treated by the Respiratory, Dermatology and other departments, with the listed medications, during the period 1 February to 30 April 2026.

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)	72	0	16
4.2 Depemokimab (Exdensur)	0	0	0
4.3 Dupilumab (Dupixent)	13	145	*
4.4 Lebrikizumab (Ebglyss)	0	5	0
4.5 Mepolizumab (Nucala)	21	0	5
4.6 Omalizumab (Xolair)	0	10	*
4.7 Reslizumab (Cinqaero)	0	0	0
4.8 Tezepelumab (Tezspire)	126	0	42